Previous close | 6.38 |
Open | 6.42 |
Bid | 6.26 x 100 |
Ask | 6.54 x 100 |
Day's range | 6.00 - 6.44 |
52-week range | 5.92 - 18.65 |
Volume | |
Avg. volume | 103,703 |
Market cap | 117.573M |
Beta (5Y monthly) | 0.44 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.44 |
Earnings date | 07 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 22.00 |
Performance Analysis and Future Outlook Amidst Clinical Progress
Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDAData presented at the 2024 AACR demonstrate NXP900's robust activity in non-small cell cancer cell linesSeveral clinical data updates expected in 2H 2024 FORT LEE, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused
Just because a business does not make any money, does not mean that the stock will go down. For example, although...